Intuitive Surgical, Inc.
ISRG · Healthcare
$369.25
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
2 Stocks Down 8% or More That Are Screaming Buys Right Now
The article highlights two beaten-down stocks as potential buying opportunities: Intuitive Surgical, down 34% year-to-date, is positioned to benefit from its da Vinci 5 surgical system's advanced features and expanding market; Novo Nordisk, down 8% this year, has promising GLP-1 pipeline candidates like amycretin and UBT251 that could help it regain market share in the weight-loss drug sector.
3 Stocks Whose Competitive Walls Tower Over Nvidia's
While Nvidia has built a strong competitive moat in AI chips, three healthcare stocks—Moderna, Intuitive Surgical, and Vertex Pharmaceuticals—possess even more formidable competitive advantages. Moderna leverages its mRNA expertise across vaccines and oncology; Intuitive Surgical dominates robotic surgery with high switching costs; and Vertex leads in cystic fibrosis treatment with a patent-protected pipeline extending to the late 2030s.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
The iShares U.S. Medical Devices ETF (IHI) is reviewed as a passively managed fund offering diversified exposure to the healthcare medical devices sector. With $3.44 billion in assets and a 0.37% expense ratio, IHI tracks the Dow Jones U.S. Select Medical Equipment Index. The fund has declined 12.46% year-to-date and carries a Zacks ETF Rank of 3 (Hold), making it a reasonable but not exceptional choice for sector exposure.
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Intuitive Surgical is prioritizing R&D investment over near-term profitability to drive long-term growth, focusing on AI/ML, robotics, and expanding into new clinical areas like GI, cardiac, and lung procedures. The company is sacrificing near-term expense leverage to build competitive moats and broaden its addressable market. Peer companies Edwards Lifesciences and Glaukos are similarly investing heavily in R&D to strengthen their competitive positions.
Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech
Intuitive Surgical faces new competition from Medtronic and Johnson & Johnson in the surgical robotics space, but maintains a strong market position with 11,710 da Vinci systems in use globally. The company's real strength lies in its recurring revenue from instruments, accessories, and services (75% of revenue), rather than system sales alone. Despite a 40% stock decline and a 42x P/E ratio, the company's large installed base and annuity-like income streams provide a competitive moat that positions it favorably for growth-oriented investors.